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The nucleoside analog cytarabine (Ara-C) is an essential component of primary and 16 
salvage chemotherapy regimens in acute myeloid leukemia (AML). After cellular 17 
uptake, Ara-C is converted into its therapeutically active triphosphate metabolite, Ara-18 
CTP, which exerts anti-leukemic effects primarily by inhibiting DNA synthesis in 19 
proliferating cells
1
. Currently, a substantial fraction of AML patients fails to effectively 20 
respond to Ara-C therapy and reliable biomarkers are lacking
2,3
. SAMHD1 is a 21 
deoxynucleoside triphosphate (dNTP) triphosphohydrolase that cleaves physiological 22 
dNTPs into deoxyribonucleosides and inorganic triphosphate
4,5
. Although it has been 23 
postulated that SAMHD1 sensitizes cancer cells to nucleoside analog derivatives through 24 
depletion of competing dNTPs
6
, we show here that SAMHD1 reduces Ara-C cytotoxicity 25 
in AML cells. Mechanistically, dGTP-activated SAMHD1 hydrolyzes Ara-CTP, 26 
resulting in a drastic reduction of Ara-CTP in leukemic cells. Loss of SAMHD1 activity - 27 
through genetic depletion, mutational inactivation of its triphosphohydrolase activity, or 28 
proteasomal degradation using specialized virus-like particles
7,8
 - potentiates the 29 
cytotoxicity of Ara-C in AML cells. In mouse retroviral AML transplantation models as 30 
well as in retrospective analyses of adult AML patients, the response to Ara-C-31 
containing therapy was inversely correlated with SAMHD1 expression. These results 32 
identify SAMHD1 as a potential biomarker for the stratification of AML patients to 33 
Ara-C-based therapy and as a target for treating Ara-C-refractory AML. 34 
 35 
  36 
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The current backbone of AML therapy is treatment with the cytidine analog Ara-C and the 37 
anthracycline daunorubicin. Despite a high rate of initial remissions, a substantial fraction of 38 
AML patients relapses and acquires resistance to Ara-C
1,9
. The prognosis of AML patients, 39 
especially elderly ones, remains dismal
2,9
. Mutations in the SAMHD1 gene, encoding Sterile 40 
alpha motif and histidine-aspartic domain-containing protein 1 (SAMHD1), have been 41 
associated with the Aicardi-Goutières autoimmune syndrome
10
 and the development of 42 
malignancies including cutaneous T-cell lymphoma, chronic lymphatic leukemia, and colon 43 
cancer
11-13
. SAMHD1, a dNTP triphosphohydrolase that cleaves dNTPs into 44 
deoxyribonucleosides and inorganic triphosphate, enhances the efficacy of certain nucleoside 45 
analog drugs for the treatment of human immunodeficiency virus type-1 (HIV-1) by 46 
decreasing the levels of intracellular dNTPs
14,15
, which apparently compete with the 47 
thymidine analog triphosphates for incorporation into HIV-1 cDNA during reverse 48 
transcription
16
. We postulated that SAMHD1 could have a similar effect on nucleoside 49 
analog-based therapy in leukemia
6
. 50 
To investigate whether SAMHD1 expression enhances Ara-C cytotoxicity in AML 51 
cells, we tested whether Ara-C sensitivity in 13 AML cell lines, determined by the half 52 
maximal inhibitory concentration (IC50), is correlated with SAMHD1 protein and mRNA 53 
levels. Both SAMHD1 expression (Fig. 1a and Supplementary Fig. 1) and Ara-C sensitivity 54 
(Supplementary Table 1) varied considerably among these cell lines. Unexpectedly, 55 
SAMHD1 levels inversely correlated with Ara-C cytotoxicity (p=0.0037, Fig. 1b and 56 
Supplementary Fig. 2a,b), as well as with the levels of early (Caspase 3 and 7 activity, 57 
p=0.02, Supplementary Fig. 3a,b) and late (sub-G1 cells, apoptotic DNA fragmentation, 58 
p=0.029, Supplementary Fig. 3c,d) markers of apoptosis. In contrast, no significant 59 
correlation could be established between Ara-C IC50 values and the expression of cellular 60 
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proteins previously implicated in Ara-C uptake or its conversion to Ara-CTP
1
, including 61 
equilibrative nucleoside transporter (ENT1/SLC29A1), deoxycytidine kinase (DCK), cytidine 62 
deaminase (CDA), deoxycytidilate deaminase (DCTD), or 5-nucleotidase (NT5C2) (Fig. 63 
1a,c-g). 64 
To further investigate its role in Ara-C resistance, we tested the effects of SAMHD1 65 
deficiency by a number of approaches: (i) depletion of SAMHD1 in AML cell lines 66 
expressing high endogenous SAMHD1 levels using either lentiviral vectors encoding 67 
SAMHD1-specific shRNA or transfection with SAMHD1-specific siRNA; (ii) CRISPR/Cas9-68 
mediated disruption of the SAMHD1 gene; and (iii) targeted degradation of SAMHD1 using 69 
virus-like particles (VLPs) which shuttle the SAMHD1-interacting lentiviral Vpx protein 70 
(Vpx-VLPs) into cells
7,8,17
 (Fig. 2a and Supplementary Fig. 4). Vpx recruits SAMHD1 to a 71 
cullin4A-RING E3 ubiquitin ligase (CRL4
DCAF1




SAMHD1 depletion in AML cell lines by RNA interference (OCI-AML3, THP-1), 74 
SAMHD1 knockout (THP-1
-/-
), or transduction with Vpx-VLPs (MonoMac6 cells, THP-1) 75 
markedly sensitized AML cell lines to Ara-C toxicity relative to the respective controls (Fig. 76 
2a,b and Supplementary Fig. 4). In contrast, SAMHD1 siRNA had only a marginal effect on 77 
Ara-C toxicity in low SAMHD1-expressing HEL cells (Fig. 2a,b). Interestingly, we observed 78 
SAMHD1 dependency, although less pronounced, for the purine analog fludarabine 79 
(Supplementary Fig. 5a); however, the IC50 values for the topoisomerase II inhibitors 80 
etoposide and daunorubicin, as well as for dFdC (2,2-difluorodeoxycytidine; gemcitabine), 81 
were not consistently affected by SAMHD1 down-modulation (Supplementary Fig. 5b-d), 82 
indicating a certain degree of drug specificity. 83 
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In HEL cells, an AML cell line that expresses very low endogenous levels of 84 
SAMHD1 (Fig. 1a and Fig. 2a,c), constitutive overexpression of wild-type SAMHD1 85 
(SAMHD1-WT), but not of the dNTPase-deficient SAMHD1-D311A mutant, increased the 86 
IC50 values for Ara-C and fludarabine (Fig. 2c and Supplementary Fig. 5a). In contrast, the 87 
toxicity of daunorubicin, etoposide, or dFdC was largely unaltered (Supplementary Fig. 5b-88 
d). These results indicate that SAMHD1s enzymatic activity is critically involved in 89 
mediating resistance of AML cells to Ara-C and, to a lesser extent, fludarabine. Notably, Ara-90 
C at concentrations mimicking the steady state levels of Ara-C in plasma during standard Ara-91 




 or the minimum blood plasma concentration (Cmin; achieved 92 




 only 93 
partially affected the viability of SAMHD1-expressing AML cell lines, whereas SAMHD1-94 
depleted cells were effectively killed (Supplementary Fig. 6).    95 
Although previous in vitro studies provided no evidence that triphosphorylated anti-96 
viral nucleoside analogs can be hydrolyzed by SAMHD1
19,20
, we hypothesized that SAMHD1 97 
might be able to hydrolyze Ara-CTP, which differs from the physiological dCTP substrate by 98 
only a hydroxyl substituent in the up-position at carbon atom-2 of the pentose moiety 99 
(Supplementary Fig. 7). To directly test whether Ara-CTP is hydrolyzed by SAMHD1, we 100 
quantified Ara-CTP levels relative to SAMHD1 expression following short-term exposure of 101 
AML cells to 
13
C3-Ara-C, using liquid chromatography tandem mass spectrometry (LC-102 
MS/MS). We detected 47-fold higher Ara-CTP levels in SAMHD1-deficient THP-1
-/-
 cells 103 
compared to THP-1
+/+
 control cells (Supplementary Fig. 8a), whereas SAMHD1 deficiency 104 
did not affect dFd-CTP levels after drug treatment (Supplementary Fig. 8b). Moreover, HEL 105 
SAMHD1-WT cells harbored 97- and 69-fold lower levels of Ara-CTP compared to parental 106 
HEL cells and HEL cells expressing the SAMHD1-D311A mutant, respectively (Fig. 2d). 107 
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Notably, lack of enzymatically active SAMHD1 in THP-1
-/-
 cells or in parental and 108 
SAMHD1-D311A-expressing HEL cells also resulted in elevated dNTP levels 109 
(Supplementary Fig. 9a,b), which, however, did not counteract the cytotoxicity of the 110 
concomitantly increased Ara-CTP levels (Fig. 2b,c).  111 
dGTP or GTP binding to the primary allosteric site of SAMHD1 leads to formation of 112 
a catalytically active tetramer, whereas the second allosteric site of the enzyme accommodates 113 
dNTPs
21-23
. To elucidate whether Ara-CTP can serve as a substrate or as both an activator and 114 
substrate for the triphosphohydrolase, we performed an enzymatic in vitro assay using 115 
bacterially expressed full-length SAMHD1. Analysis of reaction products by ion-pair reverse-116 
phase HPLC revealed that SAMHD1 hydrolyzes Ara-CTP to Ara-C, requiring the presence of 117 
the activator dGTP, which itself is also cleaved to dG (Fig. 2e). In specificity control 118 
experiments, the physiological substrate TTP, but not dFd-CTP, was hydrolyzed by SAMHD1 119 
(Supplementary Fig. 10a,b). Thus, Ara-CTP is a direct substrate, but not an activator, of 120 
SAMHD1s triphosphohydrolase activity in AML cells. 121 
To explore whether SAMHD1 might contribute to the development of Ara-C 122 
resistance, we gradually adapted three AML cell lines (HEL, HL-60, and Molm13), 123 
characterized by low endogenous SAMHD1 expression levels and high Ara-C sensitivity, to 124 
growth in the presence of the nucleoside analog. The resulting drug-resistant sublines were 125 





and displayed increases in Ara-C IC50 values ranging from 1643- to 4250-fold relative to the 127 
parental cell lines (Supplementary Table 2). In addition to changes in the expression of some 128 
cellular factors previously implicated in acquired Ara-C resistance (i.e., DCK, CDA, and 129 
NT5C2), the levels of SAMHD1 were markedly increased in the Ara-C-resistant sublines 130 
relative to their parental counterparts (Fig. 3a and Supplementary Fig. 11). Ara-C resistance 131 
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was accompanied by drastically decreased Ara-CTP levels (Fig. 3b) and exposure of Ara-C-132 
resistant AML cells to Vpx-VLPs depleted SAMHD1, increased Ara-CTP levels, and re-133 
sensitized the cells to Ara-C by up to 11.5-fold relative to Vpr-VLP-treated control cells (Fig. 134 
3c,d). Whereas cultivation of the parental AML cell lines in the presence of the drug for 24 h 135 
did not acutely induce SAMHD1 levels (Supplementary Fig. 12a), selection for 20 d in 136 
Molm13 cells resulted in an upregulation of SAMHD1 levels (Supplementary Fig. 12b). 137 
To study the role of SAMHD1 in AML drug sensitivity in vivo, we transformed mouse 138 
myeloid progenitor cells using the oncogenes Hoxa9/Meis1 or MN1 and subsequently deleted 139 
the SAMHD1 gene using CRISPR/Cas9 genome editing with two independent guide RNAs 140 
(gRNA). SAMHD1
+/+




) AML blasts were 141 
transplanted into irradiated recipient mice, and were treated with either Ara-C or phosphate-142 
buffered saline (PBS) on day 18 and 19 after transplantation (Supplementary Fig. 13a-d). 143 
Overall survival of the two independent mouse cohorts transplanted with SAMHD1
-/-
 AML 144 
was dramatically prolonged compared to SAMHD1
+/+
 AML by administration of Ara-C (Fig. 145 
4a,b (p=2.97x10
-6
 for both cohorts), Supplementary Fig. 13e (p=3.05x10
-6
) and 146 
Supplementary Fig. 13f (p=4.32x10
-6
)), but not by PBS treatment (Fig. 4a,b and 147 
Supplementary Fig. 13e,f). Similar results were obtained for two mouse cohorts for which a 148 
second SAMHD1 gRNA was used (Supplementary Fig. 14).    149 
In human blasts isolated from bone marrow of therapy-naïve AML patients, basal 150 
SAMHD1 expression correlated with Ara-C IC50 values (p=0.04, Supplementary Fig. 15). 151 
Moreover, we tested the effects of transient depletion of SAMHD1 in blasts of six patients 152 
(Supplementary Table 3, patients A to F). Two days after transfection with control or 153 
SAMHD1-targeting siRNA, the blasts were cultured in the presence of Ara-C or daunorubicin. 154 
SAMHD1 depletion diminished Ara-C IC50 values by 3- to 15-fold (Fig. 4c), whereas the 155 
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sensitivity of the blasts to daunorubicin was unaltered (Supplementary Table 4). Similarly, 156 
treatment with SAMHD1-degrading Vpx-VLPs sensitized primary AML blasts to Ara-C, but 157 
not to daunorubicin, compared to Vpr-containing control VLPs (Supplementary Fig. 16 and 158 
Supplementary Table 5). Concomitantly with this sensitization, intracellular Ara-CTP levels 159 
were elevated (Supplementary Fig. 8c,d). Finally, we examined the suitability of SAMHD1 160 
expression as a biomarker for predicting the response of AML to standard Ara-C-containing 161 
therapy. We analyzed an AML cohort of 150 adult patients who had received one to two 162 
courses of Ara-C-containing induction therapy in two University Hospital study centers in 163 
Germany. Patients received either two cycles of 7+3 or 7+3 plus high-dose Ara-C in 164 
combination with mitoxantrone (HAM) according to standard German AML protocols 165 
(Supplementary Table 6). The 7+3 treatment regime refers to 7 days of standard-dose 166 
Ara-C with the addition of daunorubicin for 3 days during the 7 day-chemotherapy induction 167 
cycle (see Online Methods). Retrospective analysis of SAMHD1 protein levels by 168 
immunohistochemical (IHC) staining of blasts in sections of paraffinized bone marrow 169 
isolated at primary diagnosis revealed that expression of SAMHD1 was highly variable 170 
between patients and, importantly, markedly increased in the group of AML patients that did 171 
not reach a complete remission (No CR, n=38) at the end of induction therapy, as compared 172 
to the group of patients with documented complete remission (CR, n=112) (p=6.3x10
-8
, 173 
Wilcoxon Rank Sum test) (Fig. 4d,e and Supplementary Table 6). Of the 150 patients, 112 174 
achieved CR; of these 90 were scored as SAMHD1-low and 22 were scored as SAMHD1-175 
high. The CR rate in the SAMHD1-high cohort was 22/50 (44%), whereas the CR rate in 176 
the SAMHD1-low cohort was 90/100 (90%). This difference between the two SAMHD1-177 
stratified cohorts was highly statistically significant (p=3.477x10
-9
, Chi-Squared Test  178 
with 1 degree of freedom). As a validation of the IHC staining and scoring system, levels of 179 
9
   
 
 
SAMHD1 protein expression in blasts as determined by IHC scoring and in parallel by flow 180 
cytometry showed a positive correlation (p<0.0001, Supplementary Fig. 17b). All CR 181 
patients received post-remission therapy: a high-dose Ara-C-containing chemo-consolidation 182 
regimen and/or allogeneic stem cell transplantation. In our AML cohort, the level of 183 
SAMHD1 expression in blasts at initial diagnosis was highly predictive for event-free 184 
survival (EFS) (p=1.86x10
-11
, Fig. 4f), where an event was defined as failure to achieve CR, 185 
relapse or death. Also, relapse-free survival (RFS) of CR patients was significantly worse in 186 
SAMHD1-high compared to SAMHD1-low patients (p=2.02 x10
-4
, Fig. 4g), indicating 187 
that the depth of remission in SAMHD1-high patients was less pronounced than in 188 
SAMHD1-low patients. Although the median observation time was relatively short, 189 
SAMHD1-high patients experienced a significantly worse overall survival (OS) (p=4.85 190 
x10
-3
, Fig. 4h). When patients were censored from the analyses at the time of allogeneic 191 
transplantation, all differences (EFS, RFS, OS) remained statistically significant 192 
(Supplementary Fig. 18a-c). Notably, no correlation could be established between 193 
cytogenetic risk groups and SAMHD1 expression (Supplementary Fig. 19a). In a 194 
multivariate analysis including age, gender, initial leukocyte count and cytogenetic risk group, 195 
and type of second induction cycle (HAM versus 7+3), high SAMHD1 expression proved 196 
to be an independent risk factor for EFS (hazard ratio 1.72, p=5.23x10
-8
) and OS (1.33, 197 
p=0.0228) (Supplementary Fig. 19b,c).  198 
Furthermore, mining of the publicly available AML data set of the TCGA cohort
24 
199 
confirmed a correlation between low SAMHD1 mRNA expression with CR for patients who 200 
had received an Ara-C-containing therapy (Supplementary Fig. 20). Thus, SAMHD1 levels 201 
at diagnosis inversely correlate with the clinical response to Ara-C-based therapy in two 202 
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different adult AML patient cohorts, and this prominent role of SAMHD1 in Ara-C response 203 
is corroborated by results from murine AML transplantation models. 204 
Taken together, this study identifies SAMHD1 as a cellular biomarker for stratification 205 
of patients to Ara-C-based therapy and uncovers a patient- and drug-specific interference 206 
mechanism (Supplementary Fig. 21) that, in addition to established molecular and 207 
cytogenetic risk factors
25
, determines the outcome of AML disease. Ara-Cs mimicry of the 208 
physiological nucleoside cytidine endows it with anti-leukemic activity, but this mimicry is 209 
detrimental in AML blasts that express the Ara-CTP-inactivating SAMHD1 protein. This 210 
concept applies to a lesser extent also to the purine analog fludarabine, but not to dFdC, 211 
indicating that SAMHD1 should be considered a critical cellular factor in the evaluation of all 212 
nucleoside analog-based drugs or drug candidates in AML. Future studies will determine 213 
whether protein- or mRNA-based quantification of SAMHD1 in AML blasts at diagnosis is a 214 
better predictor of the therapeutic response. In vivo strategies aiming at transient 215 
downregulation of SAMHD1 by either RNA interference or application of SAMHD1-216 
degrading Vpx-VLPs, or, conceivably, through administration of an inhibitor of SAMHD1s 217 
enzymatic activity, may improve the Ara-C-based treatment of AML and other malignancies.  218 
 219 
METHODS 220 
Methods and any associated reference are available in the online version of the paper. 221 
Note: Any Supplementary Information and Source Data files are available in the online 222 
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Legends to Figures  315 
 316 
Figure 1⏐ SAMHD1 expression levels inversely correlate with Ara-C cytotoxicity in 317 
AML cell lines. (a) Representative immunoblots of SAMHD1 and other proteins previously 318 
reported to be involved in Ara-C uptake and its conversion to the active Ara-C metabolite, 319 
Ara-CTP, in the indicated AML cell lines. ȕ-actin served as a loading control. Three 320 
independent experiments were performed. Uncropped images are shown in Supplementary 321 
Figure 22. (b-g) Correlation analyses between Ara-C IC50 values for these AML cell lines in 322 
a and the relative expression levels of SAMHD1 (b), ENT1 (c), DCK (d), CDA (e), DCTD 323 
(f), or NT5C2 (g). Expression levels were normalized to ȕ-actin and are shown as arbitrary 324 
units (a.u.); the relative expression of each protein in THP-1 cells was set to 1. For b-g, closed 325 
circles and error bars represent mean ± s.e.m. of three independent experiments each 326 
performed with technical replicates (n=3). Data in b-g were analysed using a linear regression 327 
model. R
2
 values indicate goodness of fit of the regression model to the data, and represent 328 
variance explained by the independent variable divided by total variance of the IC50 Ara-C 329 
values.  330 
 331 
Figure 2 ⏐SAMHD1 counteracts Ara-C toxicity in AML cell lines via hydrolysis of the 332 
active metabolite, Ara-CTP. (a) Representative immunoblots for SAMHD1 after 333 
CRISPR/Cas9-mediated SAMHD1 knockout in THP-1 (THP-1
-/-
) cells or after shRNA or 334 
siRNA-mediated silencing of SAMHD1 in OCI-AML3 and HEL cells. Alternatively, OCI-335 
AML3 and MonoMac6 cells were transduced with VLPs carrying either lentiviral Vpr (Vpr-336 
VLPs, control) or Vpx (Vpx-VLPs) proteins. ȕ-actin served as a loading control. Uncropped 337 
images are shown in Supplementary Figures 22 and 23. (b) Ara-C IC50 values of the 338 
15
   
 
 
experimental groups shown in a. Each circle represents a technical replicate (n=3) of three 339 
independent experiments performed. Horizontal lines and error bars represent means ± s.e.m. 340 
Numbers at the top indicate the factor of decrease of Ara-C IC50 values in SAMHD1-depleted 341 
relative to control cells. (c) Ara-C IC50 values (top) and immunoblot for SAMHD1 (bottom) 342 
in parental HEL cells or HEL cells stably transduced with either wildtype SAMHD1 343 
(SAMHD1-WT) or the dNTPase-inactive D311A SAMHD1 mutant (SAMHD1-D311A). For 344 
the IC50 data, the numbers above the bars indicate the factor by which the IC50 value differed 345 
relative to HEL SAMHD1-WT cells. The IC50 values are shown as means ± s.e.m. of three 346 
independent experiments each performed with technical replicates (n=3) represented by 347 
individual circles. ȕ-actin served as a loading control for the SAMHD1 immunoblot. 348 
Uncropped images are shown in Supplementary Figure 23. (d) Representative liquid 349 
chromatography tandem mass spectrometry (LC-MS/MS) analysis of Ara-CTP in parental 350 
HEL cells (blue chromatogram), HEL SAMHD1-WT cells (black chromatogram), or HEL 351 
SAMHD1-D311A cells (red chromatogram). (e) HPLC analysis of products from an 352 
enzymatic in vitro assay using bacterially expressed full-length SAMHD1. Ara-CTP was 353 
incubated by itself (top), in the presence of SAMHD1 (middle), or in the presence of 354 
SAMHD1 and the allosteric activator/substrate dGTP (bottom). Chromatogram peaks 355 
corresponding to Ara-C, dG, and Ara-CTP are indicated. Statistical analyses were performed 356 
using unpaired two-tailed Students t-test. For (b) the degree of freedom was 16 and p< 357 
0.0001 for all except for siRNA-treated HEL cells (df =4, p=0.0004).  df was 16 and p< 358 
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Figure 3 ⏐ SAMHD1 contributes to the acquired resistance of AML cells to Ara-C. (a)  363 
Representative immunoblots of proteins involved in Ara-C uptake and metabolism in parental 364 













). ȕ-actin served as a loading control. 366 
Three independent experiments were performed. Uncropped images are shown in 367 
Supplementary Figure 24. (b) Quantitative analysis by LC-MS/MS of Ara-CTP levels in 368 
parental and Ara-C-resistant AML cell lines. The means ± s.d. of triplicates of one 369 
representative experiment are shown; three independent experiments were performed. 370 
Numbers above the bars represent the factor of decrease in Ara-CTP levels in Ara-C-resistant 371 
cell lines relative to their parental counterparts. (c) Ara-C-resistant cell lines were treated with 372 
the indicated VLPs and subsequently analyzed for Ara-C cytotoxicity (top) and SAMHD1 373 
expression (bottom). Ara-C IC50 values of three independent experiments each performed 374 
with technical replicates (n=3) are presented with center lines showing the medians. The box 375 
limits are quartiles 1 and 3, and whiskers show maximum and minimum values. Numbers 376 
above the bars indicate the factor of decrease in IC50 values in Vpx-VLP-treated cells relative 377 





 cells treated with either Vpr-VLPs (control, black), Vpx-VLPs (red), or left 379 
untreated (blue). Statistical analyses were performed using unpaired two-tailed Students t-380 
test. For (b) the degree of freedom for all was 4 and exact p-values 0.0073 for HEL cells, 381 
0.0037 for HL-60 cells and 0.0004 for Molm13 cells. df was 16 and p< 0.0001 for 382 
(c).*p0.05; **p<0.01, ***p <0.001. 383 
 384 
Figure 4  ⏐ SAMHD1 expression in leukemic blasts predicts response to Ara-C-385 
containing therapy in mouse transplantation models and AML patients. (a,b) Kaplan-386 
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Meier survival analyses of Hoxa9/Meis1- (a) or MN1-driven (b) AML transplantation models 387 
using myeloid progenitors with endogenous SAMHD1 expression (SAMHD1
+/+
) or 388 
SAMHD1-deleted (SAMHD1
-/-
) myeloid progenitors. Ara-C: i.p. administration of 75 mg/kg 389 
Ara-C on days 18 and 19 after transplantation; Control: PBS. The difference in overall 390 




mice was statistically significant 391 
(logrank test, Hoxa9/Meis1: p=2.97x10
-6
, n=10 both groups; MN1: p=2.97x10
-6
, n=10 both 392 
groups). The differences between the two control groups and between SAMHD1
+/+
Ara-C and 393 
both control groups were not significant (Hoxa9/Meis1: p=0.42, SAMHD1
-/- 
(n=10) vs 394 
SAMHD1
+/+
 (n=9); MN1: p=0.196, n=10 both groups). (c) Blasts isolated from bone marrow 395 
from six adult AML patients (AF) were transfected with SAMHD1-specific or control 396 
siRNAs and two days later analyzed for Ara-C cytotoxicity (top) and SAMHD1 expression 397 
(bottom). Ara-C IC50 values are presented as the means ± s.d. of the triplicates shown. The 398 
numbers above the data points indicate the factor of difference between the siCTRL and 399 
siSAMHD1 groups. Uncropped images are shown in Supplementary Figure 25. (d) 400 
Representative IHC micrographs showing SAMHD1 and CD34 expression in bone marrow 401 
(BM) from one No CR patient (#39), one CR patient (#28), and one healthy donor. Scale bar: 402 
50 µm. (e) Comparison of SAMHD1 expression levels (IHC scores) in CR and No CR 403 
patients. See Online Methods for an explanation of the IHC scores. Shown are relative 404 
frequencies (in percent) of patients with IHC scores of 0, 1, 2 or 3 among CR (n=112) and No 405 
CR (n=38) patients. f-h, Kaplan-Meier analyses for event-free survival (f), relapse-free 406 
survival (g), and overall survival (h), for which AML patients were grouped into No / low 407 
SAMHD1 expressors (IHC scores 0 or 1, red curves) versus High SAMHD1 expressors 408 
(IHC scores 2 or 3, black curves). Numbers above the plots indicate the absolute number of 409 
patients in each of the two groups at the respective time points. Significance of difference 410 
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between survival curves in f,g,h was assessed using the logrank test (p-values indicated in 411 
figure). 412 
 413 
ONLINE METHODS 414 
Ethics statement. Whole blood and bone marrow biopsies of AML patients were obtained 415 
and collected pre- and post-treatment. All patients gave informed consent according to the 416 
Declaration of Helsinki to participate in the collection of samples. The use of whole blood and 417 
bone marrow aspirates was approved by the Ethics Committee of Frankfurt University 418 
Hospital (approval no. SPO-01-2015) and University Hospital Münster (approval no. 2007-419 
390-f-S). 420 
 421 
Plasmids. The SIVmac251-based gag-pol expression constructs pSIV3+R- (Vpr-deficient) 422 
and pSIV3+X- (Vpx-deficient) were previously reported
17
. pLKO.1-puro-control-shRNA and 423 
pLKO.1-puro-SAMHD1-shRNA#1-3 for shRNA-mediated silencing of SAMHD1 were 424 
previously described
15
. pHR-based transfer vectors expressing SAMHD1-WT or the D311A 425 
mutant were generated by site-directed mutagenesis in a codon-optimized SAMHD1 426 
expression construct (kindly provided by Dr. Thomas Gramberg, Institute of Clinical and 427 
Molecular Virology, FAU Erlangen-Nürnberg, Erlangen, Germany) and subcloned into pHR-428 
luc transfer vectors. pPAX2 was purchased from Addgene and pVSV-G has been previously 429 
described
26
.  430 
 431 
Cells and Reagents. Human AML cell lines including THP-1 (DSMZ no. ACC16; FAB M6), 432 
OCI-AML2 (DSMZ No. ACC 99; FAB M4), OCI-AML3 (DSMZ No. ACC 582; FAB M4), 433 
Molm13 (DSMZ No. ACC 554; FAB M5a), PL-21 (DSMZ No. ACC 536; FAB M3), HL-60 434 
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(DSMZ No. ACC 3; FAB M2), MV4-11 (DSMZ No. ACC 102; FAB M5), SIG-M5 (DSMZ 435 
No. ACC 468; FAB M5a), ML2 (DSMZ No. ACC 15; FAB M4), NB4 (DSMZ No. ACC 436 
207; FAB M3), KG1 (DSMZ No. ACC 14; FAB not indicated), MonoMac6 (DSMZ No. 437 
ACC 124; FAB M5), and HEL (DSMZ No. ACC 11; FAB M6) were obtained from DSMZ 438 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH). All cell lines were 439 
cultured in IMDM (Biochrom) supplemented with 10% FBS (SIG-M5 20% FBS), 4 mM L-440 
Glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 37°C in a humidified 5 % 441 
CO2 incubator. Cells were routinely tested for mycoplasma contamination (LT07-710, Lonza) 442 
and authenticated by short tandem repeat profiling, as reported
27
. THP-1 cells deficient for 443 
SAMHD1 (THP-1
-/-
) and control cells (THP-1
+/+
) were generated as previously described
28
 444 
and cultivated in RPMI supplemented with 10% FCS, 100 IU/ml penicillin, and 100 mg/ml 445 
streptomycin.  446 
Mononuclear cells from blood or bone marrow AML samples were purified by Ficoll-447 
Hypaque gradient centrifugation
26
. Leukemic cells were enriched by negative selection with a 448 
combination of CD3- (130-150-101), CD19- (130-150-301) and CD235a-microbeads (130-449 
150-501, all from Miltenyi Biotec) according to the manufacturers instructions and separated 450 
by the autoMACS
TM
 Pro Separator. All preparations were evaluated for purity resulting in 451 
>90% leukemic blasts. The AML-393 sample carrying a MLL-AF10 translocation was 452 
derived from a 47 year old female with AML at relapse after bone marrow transplantation. 453 
Primary cells were amplified in NSG mice and re-isolated from enlarged spleens as 454 
described
29
. Frozen cells were kindly provided by Dr. Irmela Jeremias (Department of Gene 455 
Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, 456 
Munich, Germany) and thawed for experiments. 457 
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AML blasts (2 x 10
6
) were cultivated in X-vivo 10 medium (Lonza) supplemented with 10% 458 
HyClone FCS (Perbio), 4 mM L-glutamine, 25 ng/ml hTPO (130-094-013), 50 ng/ml hSCF 459 
(130-096-695), 50 ng/ml hFlt3-Ligand (130-096-479) and 20 ng/ml hIL3 (130-095-069, all 460 
from Miltenyi Biotec) in 96-well plates in the presence or absence of drugs. 461 
The ecotropic GP+E86 packaging cell line was cultured in DMEM (Life Technologies) with 462 
10% heat-inactivated FCS, 2 mM L-Glutamine, 100 U/ml Penicillin and 100 µg/ml 463 
Streptomycin. Murine bone marrow cells were cultured in DMEM with 10% heat-inactivated 464 
FCS, 2 mM L-Glutamine, 100 U/ml Penicillin and 100 µg/ml Streptomycin supplemented 465 
with 10ng/ml murine recombinant IL3 (213-13), 10 ng/ml human recombinant IL6 (200-06), 466 
and 100ng/ml murine recombinant SCF (250-03) (all from Peprotech).  467 
Ara-C was purchased from Tocris (147-94-4), daunorubicin from Selleckchem (S3035), 468 
etoposide from TEVA (45891.00), fludarabine from Tocris (21679-14-1) and dFdC 469 
(gemcitabine) from Accord Healthcare GmbH (82092.00.00). Deoxynucleosides (dNs) 470 
(Sigma-Aldrich), which are dNTP precursors, were used as previously reported
15
. All 471 
nucleotide standards and internal standards for the LC-MS/MS analysis were obtained from 472 
Sigma-Aldrich, Silantes or Alsachim
30
. Labeled cytarabine, 
13
C3-Ara-C (SC-217994, Santa 473 
Cruz), was used for LC-MS/MS analysis. 474 
 475 
Generation of Ara-C-resistant cell lines. Ara-C-resistant cell lines were established by 476 
continuous exposure of  Ara-C sensitive cell lines HL-60, HEL, Molm13, THP-1, MV4-11, 477 
OCI-AML3 to increasing drug concentrations as previously described
31,32
 and are part of the 478 
Resistant Cancer Cell Line (RCCL) collection 479 
(http://www.kent.ac.uk/stms/cmp/RCCL/RCCLabout). Briefly, cells were cultured at 480 
increasing Ara-C concentrations starting with concentrations that inhibited viability of the 481 
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parental cell lines by 50 % (IC50). Ara-C concentrations were doubled every 2 to 6 weeks until 482 


























 and were continuously cultured in the presence of 2 µg Ara-C. Cells were 485 





Cell viability assay. The viability of AML cell lines treated with various drug concentrations 489 
was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 490 
dye reduction assay after 96 hours of incubation as described previously
33
. IC50 values were 491 
determined using CalcuSyn (Biosoft).  492 
 493 
Cytotoxic assay for AML blasts ex vivo. The cell viability of AML blasts was determined 494 
after 96 hours of incubation by the quantification of ATP levels in cell culture supernatants 495 
using the CellTiter-Glo
®
 Luminescent Cell Viability Assay (G7573, Promega) according to 496 
the manufacturers instructions. Luminescence was measured on a Tecan infinite M200 497 
(TECAN) instrument at a wavelength of 560 nm (reference wavelength 620 nm). IC50 values 498 
were determined using CalcuSyn (Biosoft). 499 
 500 
Apoptosis assays. Sub-G1 cells as a marker for DNA fragmentation in late apoptotic cells 501 
were measured according to Nicoletti by flow cytometry
34
. Briefly, Ara-C-treated and 502 
untreated cells were washed once in 1x PBS, incubated for at least 2h at 4°C with Nicoletti 503 
buffer (0.1 % trisodiumcitrate-dihydrate pH 7.4, 0.1% Triton X-100, 50 µg/ml propidium 504 
iodide), and diluted prior to measurement in 1x PBS. Samples were analyzed using a 505 
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FACSVerse (BD Biosciences) and FlowJo software (TreeStar). Alternatively, Caspase 3/7 506 
activity as a surrogate for early apoptosis was quantified by luminescence. Briefly, Ara-C-507 
treated and untreated cells were measured using the Caspase-Glo
®
 3/7 assay (G8091, 508 
Promega) according to the manufacturers instructions. Luminescence was measured on a 509 
Tecan infinite M200 (TECAN) instrument at a wavelength of 560 nm (reference wavelength 510 
620 nm). 511 
 512 
Flow cytometry. Intracellular SAMHD1 staining was performed as previously described
15
. 513 
Staining for surface markers (CD33, CD34, CD45) was applied prior to fixation. The 514 
following fluorochrome-conjugated antibodies were used: CD33-PE (130-091-732), CD34-515 
FITC (130-081-001, both from Miltenyi Biotech), and CD45-V450 (560373, BD 516 
Pharmingen), all diluted 1:11 per 10
7
 cells, and Alexa-Fluor-660 (A-21074, Invitrogen, Life 517 
technologies, 1:200). Samples were analyzed using a FACSVerse or FACSCanto II flow 518 
cytometer (BD Biosciences) and FlowJo software (TreeStar). 519 
For in vitro characterization of Hoxa9/Meis1- and MN1-transformed myeloid progenitor cells, 520 
surface-marker expression was characterized by flow cytometry using a LSRFortessa flow 521 
cytometer (BD Biosciences). Briefly, cells (2x10
5
) were washed twice with 2% FCS in PBS 522 
and stained with the following antibodies: PerCP-Cy5.5-conjugated anti-mouse Gr1 (45-523 
5931), V450-conjugated anti-mouse Mac1 (48-0112), APC-conjugated anti-mouse c-kit (17-524 
1171), PE-Cy7-conjugated anti-mouse Sca1 (25-5981), PE-conjugated anti-mouse FcİRI (12-525 
5898, all from eBioscience), and APC-H7-conjugated anti-mouse CD19 (560245, BD 526 
Bioscience). 7-AAD (BD-Bioscience) was used for exclusion of dead cells.  527 
 528 
23
   
 
 
Immunoblotting. Cells were lysed in Triton X-100 sample buffer and proteins separated by 529 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were blotted onto a 530 
nitrocellulose membrane (Thermo Scientific). The following primary antibodies were used at 531 
the indicated dilutions, SAMHD1 (12586-1-AP, Proteintech, 1:1000), β-actin (3598R-100, 532 
BioVision via BioCat, 1:2000), DCK (sc-393099, Santa Cruz, 1:500), CDA (sc-365292, Santa 533 
Cruz, 1:100), ENT1 (ab135756, Abcam, 1:500), and NT5C2 (H00022978-M02, Abnova, 534 
1:200), DCTD (NBP1-75825, Novus, 1:200). Visualization and quantification was performed 535 
using fluorescently labeled secondary antibodies (926-32210 IRDye
®
 800CW Goat anti-536 
Mouse and 926-32211 IRDye
®
 800CW Goat anti-Rabbit, LI-COR, 1:20000) and an Odyssey 537 
CLx Imaging system  (LI-COR Biosciences).  538 
 539 
Patients. Patients were admitted to the University Hospital Frankfurt between 2010 and 2014 540 
and treated for newly diagnosed AML with regimens containing standard dose Ara-C and 541 
daunorubicin (7+3) (83 patients) or Ara-C alone (1 patient) (Supplementary Table 6); an 542 
additional 66 patients admitted to the University Hospital Münster were included in the IHC 543 
analyses. In addition, viable AML cells were purified from bone marrow of patients that were 544 
admitted to the University Hospital Frankfurt in 2015 and 2016 (Supplementary Table 3). 545 
Patients at the University Hospitals of Frankfurt and Münster are routinely advised to undergo 546 
a bone marrow biopsy at diagnosis. All patients consented to the scientific analyses of their 547 
data and to scientific analyses of biomaterial that was obtained for diagnostic purposes. All 548 
patients received at least one course of Ara-C at a dose of 100 mg/m
2 
over 7 days and 549 
daunorubicin at a dose of 60 mg/m
2
 over 3 days (7+3) (if not otherwise stated). All patients 550 
below the age of 60 received a second cycle of induction therapy. Patients over the age of 60 551 
received a second induction cycle only if their day 15 bone marrow aspirate showed more 552 
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than 5% blasts. For the analyses, patient records were reviewed by physicians who were 553 
unaware of the SAMHD1 expression results in the diagnostic biopsies. Remission criteria and 554 
cytogenetic risk groups were assessed according to the ELN guidelines. 555 
The initial response to induction therapy was analyzed in bone marrow biopsies/aspirates and 556 
defined as complete (CR) if the blast count was <5%, and as No CR if the blast count was 557 
>5%. For the calculation of event-free survival (EFS), events were defined as failure to 558 
achieve complete remission (CR, CRi, CRp) within 40 days after the last induction cycle, 559 
relapse, or death at any time after start of therapy. Relapse-free survival (RFS) and remission 560 
duration were calculated only in patients that achieved CR. 561 
 562 
Immunostaining of bone marrow samples. Bone marrow samples from 154 patients, 563 
including 150 AML patients and four healthy donors, were provided by the University 564 
Hospital Frankfurt and University Hospital Münster, Germany. Tissues were fixed in 4% 565 
buffered formalin, descaled by EDTA and embedded in paraffin.  Immunohistochemical 566 
staining was performed as previously described
35
. Briefly, 2-ȝm bone marrow tissue sections 567 
were incubated with EnVision Flex Target Retrieval Solution, pH low (K8005, DAKO) and 568 
stained with primary antibodies directed against SAMHD1 (12586-1-AP, Proteintech, 1:3000) 569 
and against CD34 (IR632, DAKO) for 40 min at room temperature. Polymeric secondary 570 
antibodies coupled to HRPO peroxidase and DAB were used for visualization (REAL 571 
EnVision Peroxidase/DAB+, K5007, DAKO). Tissue samples were analyzed by light 572 
microscopy after counterstaining with Meyers haematoxylin (K8008, DAKO). 573 
Two pathologists, who were blinded to clinical history and therapeutic response, 574 
independently scored the SAMHD1 IHCs. They evaluated all tissue sections for nuclear 575 
SAMHD1 staining using a four-stage staining score: 0 = negative, 1 = weak intensity of 576 
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staining, 2 = strong intensity of staining in less than 25% of blasts, 3 = strong intensity of 577 
staining in more than 25% of blasts. IHC staining scores of 0 and 1 were defined as No / low 578 
expression and IHC staining scores of 2 and 3 were defined as High SAMHD1 expression. 579 
Membranous CD34 staining for the quantification of the number of AML blasts was 580 
evaluated using a two-stage staining score: 0 = negative, 1 = positive. 581 
 582 
Retrospective analysis of the TCGA AML cohort. Clinical data, mutational profiles and 583 
normalized gene expression data for a cohort of 200 AML patients from The Cancer Genome 584 
Atlas (TCGA, run date 20150821)
24
 were retrieved using the RTCGA-Toolbox 585 
R/BioConductor package, version 2.2.2
36
. All analyses were performed using R 3.3.0 and 586 
custom scripts. To test the association between SAMHD1 expression and first complete 587 
remission, all Ara-C-treated patients with available gene expression data were considered. To 588 
test the association between SAMHD1 expression and cytogenetic risk, all patients with 589 
available gene expression data were considered. For analysis of mutation rates, all patients 590 
with available mutational profiles were considered. 591 
 592 
Mice and retroviral infection of lineage-depleted bone-marrow cells. C57BL/6J female 593 
mice (age: 8-12 weeks) were obtained from Janvier-Labs (Le Genest-Saint-Isle, France). All 594 
animal experiments were performed according to the regulations of the United Kingdom 595 
Home Office and German authorities. All animal experiments were performed according to 596 
national and international standards. Bone marrow cells were harvested from mice, and 597 
lineage-negative cells were obtained by negative selection using the Lineage Cell Depletion 598 
Kit (130-090-858, Miltenyi Biotec) as recommended by the manufacturer. Lineage-negative 599 
cells were co-cultured with GP+E86 cells packaging MSCV-Hoxa9-PGK-neo in the presence 600 
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of polybrene (10 µg/ml, Sigma-Aldrich) for 3 days followed by co-incubation with GP+E86 601 
MSCV-Meis1-IRES-YFP for 1 day. Hoxa9-expressing cells were selected with 0.6 mg/ml 602 
G418 (Sigma-Aldrich) for at least 5 days. MN1-overexpressing myeloid progenitor cells were 603 
generated as described previously
37
. After selection, cells were sorted with a FACS BD Aria 604 
III cell sorter. Lentiviral transductions of cultured cells with pLentiCRISPRv2 vectors 605 
encoding SAMHD1-specific CRISPR or control vectors were performed as described 606 
previously
35
 using BU033 (5 CACCGgacgatcctcatccaaaaa 3) and BU034 (5 607 
AAACtttttggatgaggatcgtcC 3) (Fig. 4a,b), or BU035 (5 CACCGgatgattctgataaggaga 3) and 608 
BU036 (5 AAACtctccttatcagaatcatcC 3) (Supplementary Fig. 14). 609 
 610 
Transplantation and monitoring analyses of transplanted mice. 7.5x10
4
 cells were 611 
transplanted together with 2x10
5
 support cells by injection into the tail vein of lethally 612 
irradiated (9.5 Gy) recipient mice (C57BL/6J). Wild-type mononuclear bone marrow cells 613 
isolated from C57BL/6J mice and purified on a Ficoll gradient (Sigma-Aldrich) were used as 614 
support cells to reconstitute hematopoiesis in irradiated recipient mice. 18 days after 615 
transplantation, mice were treated with 75 mg/kg cytarabine or PBS (i.p.) for 2 subsequent 616 
days. 617 
Blood and bone marrow cells were isolated from mice for further analyses. Blood counts were 618 
analyzed with ScilVet abc animal blood cell counter (Scil Animal Care Company). Cells from 619 
spleen and bone marrow were incubated for 10 min with erythrocyte lysis buffer (155 mM 620 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) and then washed twice with 2% FCS in PBS. 621 
Staining was performed as described above. 622 
Blood smears and purified cells from bone marrow and spleen were centrifuged on cover slips 623 
(2x10
5
 cells/slip). Subsequently, cells were fixed for 10 min with methanol and stained with a 624 
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May-Grünwald solution for 8 min followed by Giemsa (both Merck Millipore) staining for 20 625 
min. 626 
 627 
mRNA analyses. RNA extraction and TaqMan-based mRNA quantification of SAMHD1 628 
(Applied Biosystems: assay no. Hs00210019-m1) and RNaseP (Applied Biosystems: 629 
TaqMan® RNase P Control Reagents Kit (4316844), endogenous reference control) were 630 
performed essentially as reported
38
.  631 
 632 
LC-MS/MS analysis. Cells (5 x 10
5
) were treated with 10 µg/ml 
13
C3-Ara-C (SC-217994, 633 
Santa Cruz) and incubated at 37°C in a humidified 5 % CO2 incubator for 6 h. Subsequently, 634 
cells were washed twice in 1 ml PBS, pelleted and stored at -20°C until measurement. The 635 
concentrations of dNTPs, 
13
C3-Ara-CTP, and dFdC-TP in the samples were analyzed by 636 
liquid chromatography-electrospray ionization-tandem mass spectrometry essentially as 637 
previously described
30
. Briefly, the analytes were extracted by protein precipitation with 638 
methanol. An anion exchange HPLC column (BioBasic AX, 150 x 2.1 mm, Thermo) was 639 
used for the chromatographic separation and a 5500 QTrap (Sciex) instrument was used to 640 
analyze the samples, operating as triple quadrupole in positive multiple reaction monitoring 641 
(MRM) mode. Analysis of dNTPs was performed as previously described
30
. Additionally, 642 
13




N3-5-triphosphate as an 643 
internal standard (IS). The precursor-to-product ion transitions used as quantifiers were m/z 644 
487.0 Æ 115.1 for 13C3-Ara-CTP and m/z 504 Æ 326 for dFd-CTP. Due to the lack of 645 
commercially available standards of 
13
C3-Ara-CTP and dFd-CTP, relative quantification was 646 
performed by comparing the peak area ratios (analyte/IS) of the differently treated samples. 647 
 648 
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Production of lentiviral expression vectors and VLPs. Lentiviral vectors expressing 649 
SAMHD1-WT or SAMHD1-D311A were generated by co-transfection of packaging vector 650 
pPAX2, either pHR-SAMHD1-WT or pHR-SAMHD1-D311A and a plasmid encoding VSV-651 
G. VLPs, carrying either Vpx or Vpr from SIVmac251, were produced by co-transfection of 652 
293T cells with pSIV3+ gag pol expression plasmids and a plasmid encoding VSV-G. The 653 
SAMHD1 degradation capacity of Vpx-VLPs was determined in THP-1 cells 24 h post 654 
transduction by intracellular SAMHD1 staining.  655 
 656 
Manipulation of intracellular SAMHD1 levels. For shRNA-mediated silencing of 657 
SAMHD1, OCI-AML3 cells were transduced by spinoculation with VSV-G pseudotyped 658 
lentiviral vectors carrying either pLKO.1-puro-control-shRNA or pLKO.1-puro-SAMHD1-659 
shRNA#1-3. On day 10 after transduction, successfully transduced cells were selected with 660 
puromycin (P8833, Sigma-Aldrich) (7.5 ȝg/ml). SAMHD1 levels were monitored by 661 
intracellular SAMHD1 staining and Western blotting. For siRNA-mediated silencing, AML 662 
cells (1.2 x 10
6
) were transfected with 2.5 µM ON-TARGET plus human SAMHD1 siRNA 663 
SMART-pool (L-013950-01-0050, Dharmacon) in resuspension electroporation buffer R 664 
(Invitrogen) using the Neon transfection system (Invitrogen). Additionally, ON-TARGET 665 
plus Non-targeting Pool (D-001810-10-50, Dharmacon) was transfected in parallel. 666 
Electroporation was performed using one 20 msec pulse of 1700 V and analyzed 48 h post-667 
transfection via Western blotting and cell viability assay. The following siRNA duplexes were 668 
used: non-targeting (UGGUUUACAUGUCGACUAA;UGGUUUACAUGUUGUGUGA; 669 
UGGUUUACAUGUUUUCUGA; UGGUUUACAUGUUUUCCUA),  670 
SAMHD1 (GACAAUGAGUUGCGUAUUU; CAUGUUUGAUGGACGAUUU; 671 
AAGUAUUGCUAGACGUGAA; UUAGUUAUAUCCAGCGAUU).  672 
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HEL cells were transduced by spinoculation with VSV-G pseudotyped lentiviral vectors 673 
carrying either SAMHD1-WT or the D311A mutant. Expression of SAMHD1 was monitored 674 
by intracellular SAMHD1 staining and Western blotting. AML cell lines and primary AML 675 
blasts were spinoculated with VSV-G pseudotyped VLPs carrying either Vpx or Vpr.  676 
 677 
HPLC assays for hydrolysis. To investigate whether or not Ara-CTP or dFd-CTP are 678 
hydrolyzed by SAMHD1, HPLC assays were performed as described previously
39
. The 679 
reaction mixtures (50 ȝl) contained 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 100 mM NaCl, 680 
1 mM DTT, 1 mM Ara-CTP or dFdCTP, 0.2 mM activator (dGTP), and SAMHD1 (4 µM). In 681 
some experiments, the SAMHD1 substrate TTP was used as positive control. Reaction 682 
mixtures were incubated at 37°C and passed through 10K VWR Centrifugal Filters to quench 683 
the reactions and remove the protein. Reaction products were analyzed by ion-pair reverse-684 
phase HPLC using a Varian Pursuit C18 column (150 × 4.6 mm) in a Varian ProStar HPLC 685 
system with a photodiode array detector set at 260 nm. The mobile phase for separation of 686 
nucleotides consisted of two eluants: 0.1 mM KH2PO4 (pH 6.0) with 8 687 
mM tetrabutylammonium hydroxide and 0.1 mM KH2PO4 (pH 6.0) with 8 688 
mM tetrabutylammonium hydroxide and 30 % methanol. 689 
 690 
Statistical analysis. Statistical data analysis was performed using GraphPad Prism. Linear 691 
regression and nonlinear fitting using one phase decay was used to assess correlation of 692 
protein expression, mRNA levels, or IC50 values (Fig. 1, Supplementary Figs. 2,3,15,17). R² 693 
were used to assess the quality of the fit. Unpaired group comparisons were performed using 694 
Students t-test. In Supplementary Fig. 11, paired group comparisons were performed using   695 
Students t-test. F-test was used to assess significance of regression models (Supplementary 696 
30
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Fig. 3). Comparisons of multiple groups were performed using 1-way ANOVA.  Statistical 697 
data analysis of AML patient data was performed in R version 3.2.5  698 
(R Core Team, 2016, https://www.R-project.org/), using Kaplan-Meier analysis and logrank 699 
test for survival analysis.  700 
 701 
Data availability 702 
The Cancer Genome Atlas data (TCGA) can be retrieved using the RTCGA-Toolbox 703 
R/BioConductor package, version 2.2.2. Plasmids are available upon request. 704 
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Editorial summary  744 
The therapeutic response of acute myeloid leukemia to the nucleoside analog Ara-C is 745 
regulated by SAMHD1, an enzyme which is differentially expressed in this cancer and which 746 
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